Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Morning sweating and shakiness on Cymbalta (duloxetine) usually trace back to how the drug boosts norepinephrine and serotonin, which overstimulates the sympathetic "fight or flight" system and the brain's temperature control center, producing hyperhidrosis and tremor. Timing matters too: overnight drug levels drop, so early hours can bring mild interdose withdrawal, while a natural morning cortisol and adrenaline surge amplifies jitteriness, and symptoms often ease after several weeks or with a dose or timing adjustment. Less commonly, these signs point to something needing prompt attention, such as serotonin syndrome, low blood sugar, thyroid issues, alcohol or caffeine interactions, or discontinuation effects from missed doses. There are several important distinctions to consider, including which symptoms are harmless adjustment effects and which are red flags, so see below for the complete answer before deciding what to do next.
Because sweating and tremor can come from your medication, your dose schedule, or an unrelated condition, sorting out the cause quickly is worth it, and a free, instant, online symptom check can help you clarify what is likely driving your morning symptoms and guide your next steps with a clinician.
Last reviewed for medical accuracy: 09/14/2026
Why Cymbalta Makes You Sweat and Shake in the Morning
Cymbalta (duloxetine) is a popular SNRI (serotonin-norepinephrine reuptake inhibitor) prescribed for depression, anxiety, fibromyalgia and certain types of chronic pain. While many find relief with Cymbalta, some experience side effects—most commonly sweating (hyperhidrosis) and shakiness (tremor). Understanding why these occur, especially in the morning, can help you manage them effectively and know when to seek medical advice.
Cymbalta increases the levels of two brain chemicals:
By blocking their reuptake (reabsorption), duloxetine boosts their activity. However, altering these neurotransmitters can also activate parts of the autonomic nervous system, leading to symptoms like sweating and tremors.
Most people report sweating and shaking shortly after waking. Possible reasons include:
Medication Levels and Timing
Circadian Cortisol Surge
Autonomic Nervous System Activation
Most people tolerate Cymbalta well, but up to 25% report one or more side effects, including:
These usually improve within a few weeks as your body adjusts. If sweating and tremors persist beyond 4–6 weeks or worsen, contact your healthcare provider.
Factors that increase your risk include:
You don’t have to just “tough it out.” Try these practical steps:
While mild sweating and tremor can be a normal side effect, contact your healthcare provider if you experience:
Always seek immediate medical attention for severe or alarming symptoms.
If you’re unsure whether your symptoms are normal or need urgent care, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you decide if you should adjust your medication, seek routine medical advice or head to the emergency room.
free, online symptom check, using the doctor approved Ubie Symptom Checker
Morning sweating and shakiness on Cymbalta are relatively common and often improve as your body adapts. Key strategies include adjusting dose timing, hydrating, moderating caffeine and maintaining a calm morning routine. Persistent or severe symptoms warrant medical evaluation.
Remember:
Your healthcare provider is your best partner in balancing the benefits of Cymbalta with any side effects. Regular check-ins and open communication can keep you on track toward feeling better—without unwanted sweats and shakes.
(References)
* Gelener P, Gorgulu U, Kutlu G, Ucler S, Inan LE. Serotonin syndrome due to duloxetine. Clin Neuropharmacol. 2011 May-Jun;34(3):127-8. doi: 10.1097/WNF.0b013e31821b3aa0. PMID: 21586918.
* Ormseth MJ, Scholz BA, Boomershine CS. Duloxetine in the management of diabetic peripheral neuropathic pain. Patient Prefer Adherence. 2011;5:343-56. doi: 10.2147/PPA.S16358. Epub 2011 Jul 19. PMID: 21845034; PMCID: PMC3150163.
* Riediger C, Schuster T, Barlinn K, Maier S, Weitz J, Siepmann T. Adverse Effects of Antidepressants for Chronic Pain: A Systematic Review and Meta-analysis. Front Neurol. 2017;8:307. doi: 10.3389/fneur.2017.00307. Epub 2017 Jul 14. PMID: 28769859; PMCID: PMC5510574.
* Shelton RC. Serotonin and Norepinephrine Reuptake Inhibitors. Handb Exp Pharmacol. 2019;250:145-180. doi: 10.1007/164_2018_164. PMID: 30838456.
* Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TTH. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry. 2020 Jun 16;20(1):308. doi: 10.1186/s12888-020-02711-z. Epub 2020 Jun 16. PMID: 32546134; PMCID: PMC7298955.
* Maideen NMP, Rajkapoor B, Muthusamy S, Ramanathan S, Thangadurai SA, Sughir AA. A Review on Pharmacokinetic and Pharmacodynamic Drug Interactions of Adrenergic β-blockers with Clinically Relevant Drugs-An Overview. Curr Drug Metab. 2021;22(9):672-682. doi: 10.2174/1389200222666210614112529. PMID: 34182907.
* Li L, Mi Q. Serotonin Syndrome From Duloxetine Monotherapy: A Case Report. Cureus. 2023 Jun;15(6):e40933. doi: 10.7759/cureus.40933. Epub 2023 Jun 25. PMID: 37496538; PMCID: PMC10368303.
* Siwek M, Woroń J, Wrzosek A, Gupało J, Chrobak AA. Harder, better, faster, stronger? Retrospective chart review of adverse events of interactions between adaptogens and antidepressant drugs. Front Pharmacol. 2023;14:1271776. doi: 10.3389/fphar.2023.1271776. Epub 2023 Sep 27. PMID: 37829299; PMCID: PMC10565488.
* Vigano M, Kubal S, Lu Y, Habib S, Samarani S, Cama G, Viau C, Farzin H, Koudieh N, Xia J, Ahmad A, Vigano A, Costiniuk CT. Impact of Cannabidiol and Exercise on Clinical Outcomes and Gut Microbiota for Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors: A Case Report. Pharmaceuticals (Basel). 2024 Jun 25;17(7). doi: 10.3390/ph17070834. Epub 2024 Jun 25. PMID: 39065685; PMCID: PMC11279394.
* Wang Z, Tian J, Dai W, Zhang N, Wang J, Li Z. The Effectiveness and Safety Analysis of Duloxetine in Treating Comorbid Depression in Parkinson's Disease: A Retrospective Study. Actas Esp Psiquiatr. 2024 Oct;52(5):607-615. doi: 10.62641/aep.v52i5.1634. PMID: 39403917; PMCID: PMC11475055.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.